VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws. Verrica is a dermatology therapeutics company that develops medications for viral skin diseases requiring medical intervention.

If you would like more information about our investigation of Verrica Pharmaceuticals Inc.'s misconduct, click here.

What is this Case About: Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

Verrica has spent several years working to bring to market VP-102, the Company's investigational, proprietary, drug-device combination for the treatment of molluscum contagiosum. However, several challenges have prevented this from happening. Verrica received its first Complete Response Letter (CRL) regarding the New Drug Application (NDA) in July 2020 and its second in September 2021. On May 24, 2022, Verrica received yet another CRL from the FDA related to its NDA for VP-102. On this news, the Company's stock price fell 63.85%, to close at $2.01 per share on May 25, 2022.

Next Steps: If you own shares of Verrica Pharmaceuticals Inc. (VRCA), you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Verrica Pharmaceuticals Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:VRCA

Release Summary

Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

Release Versions

English

$Cashtags

$VRCA

Hashtags

#VRCA

#VerricaPharmaceuticals

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles

Robbins LLP

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Veritone, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Veritone, Inc. (NASDAQ: VERI) securities between October 14, 2025 and April 14, 2026. Veritone engages in the provision of artificial intelligence (“AI”) computing solutions and services.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegat...

Stockholder Alert: Robbins LLP Announces that the Shareholder Class Action Against Lamb Weston Holdings, Inc. Survived the Motion to Dismiss

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that Lamb Weston Holdings, Inc. (NYSE: LW) may face damages due to a pending securities class action lawsuit brought on behalf of investors who purchased the Company's securities between July 25, 2023 and April 3, 2024. Lamb Weston is a large producer of frozen potato products, which it sells to restaurants and retailers around the world.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6...

Investor Notice: Robbins LLP Informs Sellers of the ChampionX Corporation. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all sellers of ChampionX Corporation (NASDAQ: CHX) common stock between February 29, 2024 and April 1, 2024. ChampionX is a global provider of chemistry solutions, artificial lift systems, and highly engineered equipment and technologies for the drilling and production of oil and gas. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The a...

Back to Newsroom